BBNX
VENTE TOTALE: 22 508 titres (~435 639,53 $ US)
- Insiders
- Saint Sean
- Total bought
- —
- Total sold
- $435,640
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-09
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.4% | 55.1% | 52.6% | 100.0% | |
| Ebit Margin | -73.0% | -84.1% | -367.6% | -36169.8% | |
| Ebitda Margin | -70.1% | -82.3% | -357.4% | -35418.4% | |
| Operating Profit Margin | -71.5% | -69.5% | -298.9% | -36784.4% | |
| Pretax Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Continuous Operations Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Net Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Bottom Line Profit Margin | -73.0% | -84.1% | -367.6% | -36173.7% | |
| Current Ratio | 8.663 | 6.285 | 9.771 | 3.208 | |
| Quick Ratio | 7.961 | 5.656 | 9.654 | 3.208 | |
| Solvency Ratio | -1.710 | -0.728 | -0.834 | -0.308 | |
| Cash Ratio | 1.021 | 1.439 | 2.505 | 3.119 | |
| Price To Earnings Ratio | -16.834 | -18.461 | -22.942 | -15.649 | |
| Price To Earnings Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Price To Earnings Diluted Ratio | -16.834 | -18.461 | -22.942 | -15.649 | |
| Price To Earnings Diluted Growth Ratio | -0.407 | -0.761 | 0.722 | 0.000 | |
| Price To Book Ratio | 4.294 | 13.324 | 17.280 | -5.956 | |
| Price To Sales Ratio | 12.318 | 15.551 | 84.432 | 5,657.912 | |
| Price To Free Cash Flow Ratio | -21.965 | -19.601 | -30.833 | -16.608 | |
| Price To Operating Cash Flow Ratio | -24.250 | -20.980 | -31.215 | -16.821 | |
| Debt To Assets Ratio | 0.022 | 0.048 | 0.038 | 0.116 | |
| Debt To Equity Ratio | 0.025 | 0.095 | 0.072 | -0.024 | |
| Debt To Capital Ratio | 0.025 | 0.087 | 0.067 | -0.025 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.143 | 1.969 | 1.878 | -0.209 | |
| Working Capital Turnover Ratio | 0.575 | 0.636 | 0.213 | 0.000 | |
| Operating Cash Flow Ratio | -1.647 | -2.283 | -3.059 | -6.786 | |
| Operating Cash Flow Sales Ratio | -0.508 | -0.741 | -2.705 | -336.358 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | 1.070 | 1.012 | 1.013 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -35.027 | -4,528.500 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -4,703.143 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -26.507 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -6.973 | -6.654 | -7.683 | -14.568 | |
| Capital Expenditure Coverage Ratio | -9.614 | -14.219 | -80.709 | -77.990 | |
| Dividend Paid And Capex Coverage Ratio | -9.614 | -14.219 | -80.709 | -77.990 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -17.215 | -18.461 | -23.101 | -15.603 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.4% | ▲0.3% | ▼-10.4% |
| Ebit Margin | -73.0% | ▲11.1% | ▲9100.6% |
| Ebitda Margin | -70.2% | ▲12.2% | ▲8911.9% |
| Operating Profit Margin | -71.5% | ▼-2.0% | ▲9234.5% |
| Pretax Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Continuous Operations Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Net Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Bottom Line Profit Margin | -73.0% | ▲11.1% | ▲9101.6% |
| Current Ratio | 8.663 | ▲2.378 | ▲1.681 |
| Quick Ratio | 7.961 | ▲2.305 | ▲1.341 |
| Solvency Ratio | -1.710 | ▼-0.982 | ▼-0.815 |
| Cash Ratio | 1.021 | ▼-0.418 | ▼-1.000 |
| Price To Earnings Ratio | -16.834 | ▲1.627 | ▲1.637 |
| Price To Earnings Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Forward Price To Earnings Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Price To Earnings Diluted Ratio | -16.834 | ▲1.627 | ▲1.637 |
| Price To Earnings Diluted Growth Ratio | -0.407 | ▲0.354 | ▼-0.295 |
| Price To Book Ratio | 4.294 | ▼-9.030 | ▼-2.942 |
| Price To Sales Ratio | 12.318 | ▼-3.233 | ▼-1430.235 |
| Price To Free Cash Flow Ratio | -21.965 | ▼-2.364 | ▲0.287 |
| Price To Operating Cash Flow Ratio | -24.250 | ▼-3.270 | ▼-0.933 |
| Debt To Assets Ratio | 0.022 | ▼-0.026 | ▼-0.034 |
| Debt To Equity Ratio | 0.025 | ▼-0.070 | ▼-0.017 |
| Debt To Capital Ratio | 0.025 | ▼-0.062 | ▼-0.014 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.143 | ▼-0.826 | ▼-0.052 |
| Working Capital Turnover Ratio | 0.575 | ▼-0.061 | ▲0.219 |
| Operating Cash Flow Ratio | -1.647 | ▲0.636 | ▲1.797 |
| Operating Cash Flow Sales Ratio | -0.508 | ▲0.233 | ▲84.570 |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | ▲0.034 | ▲0.054 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲1140.882 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲1175.786 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.627 |
| Operating Cash Flow Coverage Ratio | -6.973 | ▼-0.319 | ▲1.996 |
| Capital Expenditure Coverage Ratio | -9.614 | ▲4.605 | ▲36.019 |
| Dividend Paid And Capex Coverage Ratio | -9.614 | ▲4.605 | ▲36.019 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -17.215 | ▲1.246 | ▲1.380 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.23B | $1.01B | $1.01B | $1.01B | |
| Enterprise value | $1.21B | $989.6M | $990.4M | $989.2M | |
| EV / Sales | 12.08x | 15.20x | 82.57x | 5526.39x | |
| EV / Op. cash flow | -23.77x | -20.50x | -30.53x | -16.43x | |
| EV / Free cash flow | -21.53x | -19.15x | -30.15x | -16.22x | |
| EV / EBITDA | -17.21x | -18.46x | -23.10x | -15.60x | |
| Net debt / EBITDA | 0.34x | 0.43x | 0.52x | 0.37x | |
| Current ratio | 8.66x | 6.29x | 9.77x | 3.21x | |
| Income quality | 0.70x | 0.88x | 0.74x | 0.93x | |
| Graham net-net | $5 | $1 | $1 | -$4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $237.0M | $111.8M | $93.0M | $19.6M | |
| Invested capital | $252.2M | $123.2M | $99.2M | $26.5M | |
| Return on assets | -22.3% | -36.6% | -40.1% | -182.3% | |
| Operating ROA | -30.0% | -34.9% | -49.3% | 0.0% | |
| Return on tangible assets | -22.3% | -36.6% | -40.1% | -182.3% | |
| Return on equity | -25.5% | -72.0% | -75.2% | 38.1% | |
| Return on invested capital | -23.9% | -34.8% | -35.6% | -238.3% | |
| Return on capital employed | -24.1% | -35.2% | -36.1% | -247.0% | |
| Earnings yield | -5.9% | -5.4% | -4.4% | -6.4% | |
| Free cash flow yield | -4.6% | -5.1% | -3.2% | -6.0% | |
| Capex / Op. cash flow | -10.4% | -7.0% | -1.2% | -1.3% | |
| Capex / Depreciation | 184.2% | 148.7% | 19.2% | 37.0% | |
| Capex / Sales | 5.3% | 5.2% | 3.4% | 431.3% | |
| SG&A / Sales | 92.2% | 84.4% | 201.9% | 18712.3% | |
| R&D / Sales | 34.7% | 40.2% | 149.6% | 17557.5% | |
| Stock comp / Sales | 16.3% | 9.8% | 47.2% | 3407.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 72d | 67d | 135d | 0d | |
| Days payables outstanding | 41d | 36d | 75d | 0d | |
| Operating cycle | 250d | 234d | 215d | 0d | |
| Cash conversion cycle | 209d | 198d | 140d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+21.9%EV / Sales ▼-20.5%EV / EBITDA ▲+6.7%EV / Op. cash flow ▼-3.273Earnings yield ▼-0.005
Profitability
Return on equity ▲+0.466Return on assets ▲+0.143Return on invested capital ▲+0.109Return on capital employed ▲+0.111Operating ROA ▲+0.049Income quality ▼-0.186Tax burden 0.000
Efficiency
Days sales outstanding ▲+5.197Days payables outstanding ▲+5.193Operating cycle ▲+16.219Cash conversion cycle ▲+11.026Capex / Sales ▲+0.001R&D / Sales ▼-0.055
Balance-sheet strength
Current ratio ▲+2.378Net debt / EBITDA ▼-0.087Working capital ▲+125206000.000Invested capital ▲+129012000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+21.9%EV / Sales ▼-99.8%EV / EBITDA ▼-10.3%EV / Op. cash flow ▼-7.343Earnings yield ▲+0.005
Profitability
Return on equity ▼-0.635Return on assets ▲+1.600Return on invested capital ▲+2.144Return on capital employed ▲+2.230Operating ROA n/aIncome quality ▼-0.234Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-4.260R&D / Sales ▼-175.228
Balance-sheet strength
Current ratio ▲+5.455Net debt / EBITDA ▼-0.026Working capital ▲+217387000.000Invested capital ▲+225747000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-08 BBNX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Beta Bionics Inc. BBNX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Beta Bionics Inc.
- 2026-09-08 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Beta Bionics, Inc. (BBNX) NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 to February 24, 2026, inclusive (the “Class Period”).
- 2026-09-08 BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, Sept. 8,
- 2026-09-08 BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period").
- 2026-09-08 BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) between June 30, 2025 and February 24, 2026, inclusive.
- 2026-09-08 Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in [url="]Beta B
- 2026-09-08 Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Perio.
- 2026-09-08 Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - September 8, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
- 2026-09-08 Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between
- 2026-09-08 BBNX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Beta Bionics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm ATLANTA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics”) (NASDAQ: BBNX). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Beta Bionics''s iLet Bionic Pancreas insulin pump and the device''s safety.